Physician profile
Michael C Weaver
NPI 1760666366
$1,338.80
in general payments reported to CMS, 2019-2025
15 companies · $537 in 2025
The $537 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $34.20 · 2023: $124 · 2024: $644 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,294 · Education: $10.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,294.12 |
| Education | $10.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $264.51 | 2024-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $167.34 | 2024-2025 | |
| Ardelyx, INC. | $140.11 | 2024-2025 | Ibsrela |
| Gilead Sciences, INC. | $138.65 | 2023-2025 | |
| Abbvie INC. | $109.48 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.90 | 2024-2025 | Entyvio, Eohilia |
| Regeneron Healthcare Solutions, INC. | $92.64 | 2022-2024 | Dupixent |
| Madrigal Pharmaceuticals | $83.15 | 2024-2025 | Resmetirom, Rezdiffra |
| Qol Medical, LLC | $68.73 | 2024 | Sucraid |
| Phathom Pharmaceuticals, INC. | $68.29 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.39 | 2023 | Xifaxan, Trulance |
| Lucid Diagnostics INC. | $18.99 | 2024 | |
| Fresenius Kabi USA, LLC | $15.96 | 2023 | Idacio |
| Braintree Laboratories, INC. | $13.18 | 2023 | Sutab |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.